NR3C2 and diabetic kidney disease: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease worldwide.[1] Renin–angiotensin system inhibitors, sodium‐glucose cotransporter‐2 inhibitors, and mineralocorticoid receptor antagonists are the current standard therapies for DKD.[2] However, with these therapies, many DKD patients still progress to end‐stage kidney disease,[3] indicating an unmet need for therapies.